Date: October 7 -
10, 2025
Location: Seville, Spain
Location: Seville, Spain
Seville, here we come!
Cellistic is excited to join ESGCT 2025, with Peter Jaehn, PhD, from our Business Development team representing us. As cell and gene therapy advances rapidly, scalable development and GMP-compliant manufacturing of iPSC-derived therapies are more important than ever. We look forward to connecting with innovators driving next-generation cell therapies forward.
Supporting the Development of Cell Therapies at Scale
Bringing iPSC-based therapies to the clinic requires:
- Streamlined development from reprogramming through differentiation and expansion, with reliable gene editing strategies.
- Robust GMP-compliant manufacturing processes
- Consistent quality, reproducibility, and scalability
Our iPSC-Derived Therapy Solutions
- Pulse™ platform for Cell Line Development – accelerates and de-risks GMP Master Cell Bank (MCB) generation
- Echo™ platform for Differentiation & Manufacturing at scale – expertise across multiple cell types (T cells, macrophages, and NK cells); includes Echo™-NK, delivering 20B+ clinic-ready cells in 18 months for €3M
- STAR-CRISPR™ – Cellistic's proprietary, high-efficiency gene editing technology for multiplex edits and clear IP positioning; also available for outlicensing
- Allo Chassis™ – ready-to-use, off-the-shelf immune-cloaked iPSC lines, designed to reduce immunogenicity and accelerate early development timelines
- Comprehensive CDMO services – end-to-end support from process development to product release, including analytical development and cell banking; expert services backed by 15 years of experience to help developers move quickly from concept to clinical readiness
Let's talk about your program
Meet Peter Jaehn to explore how Cellistic’s integrated platforms, technologies and CDMO expertise can streamline the development and clinical readiness of your cell therapy product.
